semaglutide peptide side effects Comparative safety and of and tirzepatide: Implications for clinical decision-making in obesity management what medicine can you not

EMA Says No Evidence GLP-1 Drugs Like Ozempic Linked to Thyroid Cancer

Probiotic effects on inflammatory bowel disease

Safety Considerations and Risks IGF-1 LR3 is not a benign compound

Weight loss results: Key findings: At the highest dose (12 mg), participants lost an average of 24.2% of body weight Weight loss had not plateaued at 48 weeksparticipants were still losing 72% of participants with prediabetes reverted to normal blood sugar Improvements in blood pressure, lipids, and other metabolic markers Context: These results exceed those seen with semaglutide (~15-17% in trials) and are comparable to or slightly better than tirzepatide (~21% at highest doses)

The once-weekly dosing schedule has made it incredibly easy to integrate into my routine